mRECIST for HCC: performance and novel refinements
JM Llovet, R Lencioni - Journal of hepatology, 2020 - Elsevier
Summary In 2010, modified RECIST (mRECIST) criteria were proposed as a way of
adapting the RECIST criteria to the particularities of hepatocellular carcinoma (HCC). We …
adapting the RECIST criteria to the particularities of hepatocellular carcinoma (HCC). We …
Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002–2020)
PK Haber, M Puigvehí, F Castet, V Lourdusamy… - Gastroenterology, 2021 - Elsevier
Background & Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer-related
mortality, with a rapidly changing landscape of treatments. In the past 20 years, numerous …
mortality, with a rapidly changing landscape of treatments. In the past 20 years, numerous …
Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide.(1, 2) This neoplasm has some unique characteristics. It occurs in most cases …
worldwide.(1, 2) This neoplasm has some unique characteristics. It occurs in most cases …
Scientific rationale for combined immunotherapy with PD-1/PD-L1 antibodies and VEGF inhibitors in advanced hepatocellular carcinoma
M Kudo - Cancers, 2020 - mdpi.com
A successful phase III trial for the combination of atezolizumab and bevacizumab (the
IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported. This is …
IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported. This is …
Recent advances in systemic therapy for hepatocellular carcinoma in an aging society: 2020 update
M Kudo - Liver Cancer, 2020 - karger.com
Systemic therapy for hepatocellular carcinoma (HCC) has changed markedly since the
introduction of the molecular targeted agent sorafenib in 2007. Sorafenib increased the …
introduction of the molecular targeted agent sorafenib in 2007. Sorafenib increased the …
Fasting improves therapeutic response in hepatocellular carcinoma through p53-dependent metabolic synergism
J Krstic, I Reinisch, K Schindlmaier, M Galhuber… - Science …, 2022 - science.org
Cancer cells voraciously consume nutrients to support their growth, exposing metabolic
vulnerabilities that can be therapeutically exploited. Here, we show in hepatocellular …
vulnerabilities that can be therapeutically exploited. Here, we show in hepatocellular …
Local and regional therapies for hepatocellular carcinoma
Local and regional therapies are recommended for patients with hepatocellular carcinoma
(HCC) in very early (Barcelona Clinic Liver Cancer [BCLC] 0), early (BCLC A), and …
(HCC) in very early (Barcelona Clinic Liver Cancer [BCLC] 0), early (BCLC A), and …
Emerging agents and regimens for hepatocellular carcinoma
XD Zhu, HC Sun - Journal of hematology & oncology, 2019 - Springer
Liver cancer, mostly hepatocellular carcinoma (HCC), is the second leading cause of cancer
mortality globally. Most patients need at least one systemic therapy at different phases of …
mortality globally. Most patients need at least one systemic therapy at different phases of …
New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma
M Kudo - International journal of clinical oncology, 2022 - Springer
Since the approval of sorafenib for the treatment of unresectable hepatocellular carcinoma
in 2007 (in 2009 in Japan), five more regimens have been approved: lenvatinib, and …
in 2007 (in 2009 in Japan), five more regimens have been approved: lenvatinib, and …
The current landscape of clinical trials for systemic treatment of HCC
F Foerster, PR Galle - Cancers, 2021 - mdpi.com
Simple Summary Liver cancer is a life-threatening disease. Apart from surgery and catheter-
guided therapies, drugs are a central pillar for its treatment. Clinical trials are research …
guided therapies, drugs are a central pillar for its treatment. Clinical trials are research …